License agreement centered around technology enabling dual-payload ADC Unique combination of Synaffix’s exatecan-based technology with Qurient’s CDK7 inhibitor Amsterdam, The Netherlands and Seongnam-Si, Korea, 25 September 2025 — Synaffix B.V. (“Synaffix”), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with potential best-in-class therapeutic index, today jointly […]